View Item 

Show simple item record

Antibody‐independent targeted quantification of TMPRSS2‐ERG fusion protein products in prostate cancer
dc.contributor.authorHe, Jintang
dc.contributor.authorSun, Xuefei
dc.contributor.authorShi, Tujin
dc.contributor.authorSchepmoes, Athena A.
dc.contributor.authorFillmore, Thomas L.
dc.contributor.authorPetyuk, Vladislav A.
dc.contributor.authorXie, Fang
dc.contributor.authorZhao, Rui
dc.contributor.authorGritsenko, Marina A.
dc.contributor.authorYang, Feng
dc.contributor.authorKitabayashi, Naoki
dc.contributor.authorChae, Sung-Suk
dc.contributor.authorRubin, Mark A.
dc.contributor.authorSiddiqui, Javed
dc.contributor.authorWei, John T.
dc.contributor.authorChinnaiyan, Arul M.
dc.contributor.authorQian, Wei-Jun
dc.contributor.authorSmith, Richard D.
dc.contributor.authorKagan, Jacob
dc.contributor.authorSrivastava, Sudhir
dc.contributor.authorRodland, Karin D.
dc.contributor.authorLiu, Tao
dc.contributor.authorCamp, David G.
dc.date.accessioned2017-01-10T20:52:19Z
dc.date.available2017-01-10T20:52:19Z
dc.date.issued2014-10
dc.identifier.citation(2014). "Antibody‐independent targeted quantification of TMPRSS2‐ERG fusion protein products in prostate cancer." Molecular Oncology 8(7): 1169-1180.
dc.identifier.issn1574-7891
dc.identifier.issn1878-0261
dc.identifier.urihttps://hdl.handle.net/2027.42/135707
dc.publisherWiley Periodicals, Inc.
dc.subject.otherPRISM-SRM
dc.subject.otherProstate cancer
dc.subject.otherERG protein isoform
dc.subject.otherTargeted quantification
dc.subject.otherTMPRSS2-ERG gene fusion
dc.titleAntibody‐independent targeted quantification of TMPRSS2‐ERG fusion protein products in prostate cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USA
dc.contributor.affiliationumMichigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
dc.contributor.affiliationotherDivision of Cancer Prevention, National Cancer Institute, Rockville, MD, USA
dc.contributor.affiliationotherBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
dc.contributor.affiliationotherEnvironmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA, USA
dc.contributor.affiliationotherDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135707/1/mol22014871169-sup-mmc1.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135707/2/mol22014871169.pdf
dc.identifier.doi10.1016/j.molonc.2014.02.004
dc.identifier.sourceMolecular Oncology
dc.identifier.citedreferencePicotti, P., Clement-Ziza, M., Lam, H., Campbell, D.S., Schmidt, A., Deutsch, E.W., Rost, H., Sun, Z., Rinner, O., Reiter, L., Shen, Q., Michaelson, J.J., Frei, A., Alberti, S., Kusebauch, U., Wollscheid, B., Moritz, R.L., Beyer, A., Aebersold, R., 2013. A complete mass-spectrometric map of the yeast proteome applied to quantitative trait analysis. Nature. 494, 266 – 270.
dc.identifier.citedreferenceHuttenhain, R., Soste, M., Selevsek, N., Rost, H., Sethi, A., Carapito, C., Farrah, T., Deutsch, E.W., Kusebauch, U., Moritz, R.L., Nimeus-Malmstrom, E., Rinner, O., Aebersold, R., 2012. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci. Transl Med. 4, 142ra194
dc.identifier.citedreferenceKeshishian, H., Addona, T., Burgess, M., Mani, D.R., Shi, X., Kuhn, E., Sabatine, M.S., Gerszten, R.E., Carr, S.A., 2009. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell Proteomics. 8, 2339 – 2349.
dc.identifier.citedreferenceKuhn, E., Whiteaker, J.R., Mani, D.R., Jackson, A.M., Zhao, L., Pope, M.E., Smith, D., Rivera, K.D., Anderson, N.L., Skates, S.J., Pearson, T.W., Paulovich, A.G., Carr, S.A., 2012. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol. Cell Proteomics. 11, M111 013854
dc.identifier.citedreferenceKumar-Sinha, C., Tomlins, S.A., Chinnaiyan, A.M., 2008. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer. 8, 497 – 511.
dc.identifier.citedreferenceLange, V., Picotti, P., Domon, B., Aebersold, R., 2008. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 4, 222
dc.identifier.citedreferenceMacLean, B., Tomazela, D.M., Shulman, N., Chambers, M., Finney, G.L., Frewen, B., Kern, R., Tabb, D.L., Liebler, D.C., MacCoss, M.J., 2010. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 26, 966 – 968.
dc.identifier.citedreferenceMaher, C.A., Palanisamy, N., Brenner, J.C., Cao, X., Kalyana-Sundaram, S., Luo, S., Khrebtukova, I., Barrette, T.R., Grasso, C., Yu, J., Lonigro, R.J., Schroth, G., Kumar-Sinha, C., Chinnaiyan, A.M., 2009. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc. Natl. Acad. Sci. U S A. 106, 12353 – 12358.
dc.identifier.citedreferenceMosquera, J.M., Mehra, R., Regan, M.M., Perner, S., Genega, E.M., Bueti, G., Shah, R.B., Gaston, S., Tomlins, S.A., Wei, J.T., Kearney, M.C., Johnson, L.A., Tang, J.M., Chinnaiyan, A.M., Rubin, M.A., Sanda, M.G., 2009. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin. Cancer Res. 15, 4706 – 4711.
dc.identifier.citedreferencePark, K., Tomlins, S.A., Mudaliar, K.M., Chiu, Y.L., Esgueva, R., Mehra, R., Suleman, K., Varambally, S., Brenner, J.C., MacDonald, T., Srivastava, A., Tewari, A.K., Sathyanarayana, U., Nagy, D., Pestano, G., Kunju, L.P., Demichelis, F., Chinnaiyan, A.M., Rubin, M.A., 2010. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 12, 590 – 598.
dc.identifier.citedreferencePerner, S., Demichelis, F., Beroukhim, R., Schmidt, F.H., Mosquera, J.M., Setlur, S., Tchinda, J., Tomlins, S.A., Hofer, M.D., Pienta, K.G., Kuefer, R., Vessella, R., Sun, X.W., Meyerson, M., Lee, C., Sellers, W.R., Chinnaiyan, A.M., Rubin, M.A., 2006. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337 – 8341.
dc.identifier.citedreferencePicotti, P., Aebersold, R., 2012. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat. Methods. 9, 555 – 566.
dc.identifier.citedreferencePicotti, P., Bodenmiller, B., Mueller, L.N., Domon, B., Aebersold, R., 2009. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell. 138, 795 – 806.
dc.identifier.citedreferenceShi, T., Fillmore, T.L., Sun, X., Zhao, R., Schepmoes, A.A., Hossain, M., Xie, F., Wu, S., Kim, J.S., Jones, N., Moore, R.J., Pasa-Tolic, L., Kagan, J., Rodland, K.D., Liu, T., Tang, K., Camp, D.G., Smith, R.D., Qian, W.J., 2012. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc. Natl. Acad. Sci. U S A. 109, 15395 – 15400.
dc.identifier.citedreferenceSimicevic, J., Schmid, A.W., Gilardoni, P.A., Zoller, B., Raghav, S.K., Krier, I., Gubelmann, C., Lisacek, F., Naef, F., Moniatte, M., Deplancke, B., 2013. Absolute quantification of transcription factors during cellular differentiation using multiplexed targeted proteomics. Nat. Methods. 10, 570 – 576.
dc.identifier.citedreferenceSt John, J., Powell, K., Conley-Lacomb, M.K., Chinni, S.R., 2012. TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. J. Cancer Sci. Ther. 4, 94 – 101.
dc.identifier.citedreferenceTomlins, S.A., Aubin, S.M., Siddiqui, J., Lonigro, R.J., Sefton-Miller, L., Miick, S., Williamsen, S., Hodge, P., Meinke, J., Blase, A., Penabella, Y., Day, J.R., Varambally, R., Han, B., Wood, D., Wang, L., Sanda, M.G., Rubin, M.A., Rhodes, D.R., Hollenbeck, B., Sakamoto, K., Silberstein, J.L., Fradet, Y., Amberson, J.B., Meyers, S., Palanisamy, N., Rittenhouse, H., Wei, J.T., Groskopf, J., Chinnaiyan, A.M., 2011. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl Med. 3, 94ra72
dc.identifier.citedreferenceTomlins, S.A., Bjartell, A., Chinnaiyan, A.M., Jenster, G., Nam, R.K., Rubin, M.A., Schalken, J.A., 2009. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur. Urol. 56, 275 – 286.
dc.identifier.citedreferenceTomlins, S.A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B.E., Cao, Q., Prensner, J.R., Rubin, M.A., Shah, R.B., Mehra, R., Chinnaiyan, A.M., 2008. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 10, 177 – 188.
dc.identifier.citedreferenceTomlins, S.A., Rhodes, D.R., Perner, S., Dhanasekaran, S.M., Mehra, R., Sun, X.W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J.E., Shah, R.B., Pienta, K.J., Rubin, M.A., Chinnaiyan, A.M., 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 310, 644 – 648.
dc.identifier.citedreferencevan Leenders, G.J., Boormans, J.L., Vissers, C.J., Hoogland, A.M., Bressers, A.A., Furusato, B., Trapman, J., 2011. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod. Pathol. 24, 1128 – 1138.
dc.identifier.citedreferenceWhiteaker, J.R., Zhao, L., Anderson, L., Paulovich, A.G., 2010. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell Proteomics. 9, 184 – 196.
dc.identifier.citedreferenceZong, Y., Xin, L., Goldstein, A.S., Lawson, D.A., Teitell, M.A., Witte, O.N., 2009. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc. Natl. Acad. Sci. U S A. 106, 12465 – 12470.
dc.identifier.citedreferenceAddona, T.A., Abbatiello, S.E., Schilling, B., Skates, S.J., Mani, D.R., Bunk, D.M., Spiegelman, C.H., Zimmerman, L.J., Ham, A.J., Keshishian, H., Hall, S.C., Allen, S., Blackman, R.K., Borchers, C.H., Buck, C., Cardasis, H.L., Cusack, M.P., Dodder, N.G., Gibson, B.W., Held, J.M., Hiltke, T., Jackson, A., Johansen, E.B., Kinsinger, C.R., Li, J., Mesri, M., Neubert, T.A., Niles, R.K., Pulsipher, T.C., Ransohoff, D., Rodriguez, H., Rudnick, P.A., Smith, D., Tabb, D.L., Tegeler, T.J., Variyath, A.M., Vega-Montoto, L.J., Wahlander, A., Waldemarson, S., Wang, M., Whiteaker, J.R., Zhao, L., Anderson, N.L., Fisher, S.J., Liebler, D.C., Paulovich, A.G., Regnier, F.E., Tempst, P., Carr, S.A., 2009. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 27, 633 – 641.
dc.identifier.citedreferenceAnderson, L., Hunter, C.L., 2006. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics. 5, 573 – 588.
dc.identifier.citedreferenceAnderson, N.L., Anderson, N.G., Haines, L.R., Hardie, D.B., Olafson, R.W., Pearson, T.W., 2004. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 3, 235 – 244.
dc.identifier.citedreferenceDemichelis, F., Fall, K., Perner, S., Andren, O., Schmidt, F., Setlur, S.R., Hoshida, Y., Mosquera, J.M., Pawitan, Y., Lee, C., Adami, H.O., Mucci, L.A., Kantoff, P.W., Andersson, S.O., Chinnaiyan, A.M., Johansson, J.E., Rubin, M.A., 2007. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 26, 4596 – 4599.
dc.identifier.citedreferenceDesiere, F., Deutsch, E.W., Nesvizhskii, A.I., Mallick, P., King, N.L., Eng, J.K., Aderem, A., Boyle, R., Brunner, E., Donohoe, S., Fausto, N., Hafen, E., Hood, L., Katze, M.G., Kennedy, K.A., Kregenow, F., Lee, H., Lin, B., Martin, D., Ranish, J.A., Rawlings, D.J., Samelson, L.E., Shiio, Y., Watts, J.D., Wollscheid, B., Wright, M.E., Yan, W., Yang, L., Yi, E.C., Zhang, H., Aebersold, R., 2005. Integration with the human genome of peptide sequences obtained by high-throughput mass spectrometry. Genome Biol. 6, R9
dc.identifier.citedreferenceFalzarano, S.M., Zhou, M., Carver, P., Tsuzuki, T., Simmerman, K., He, H., Magi-Galluzzi, C., 2011. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 459, 441 – 447.
dc.identifier.citedreferenceFurusato, B., Tan, S.H., Young, D., Dobi, A., Sun, C., Mohamed, A.A., Thangapazham, R., Chen, Y., McMaster, G., Sreenath, T., Petrovics, G., McLeod, D.G., Srivastava, S., Sesterhenn, I.A., 2010. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 13, 228 – 237.
dc.identifier.citedreferenceGerber, S.A., Rush, J., Stemman, O., Kirschner, M.W., Gygi, S.P., 2003. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. U S A. 100, 6940 – 6945.
dc.identifier.citedreferenceGrasso, C.S., Wu, Y.M., Robinson, D.R., Cao, X., Dhanasekaran, S.M., Khan, A.P., Quist, M.J., Jing, X., Lonigro, R.J., Brenner, J.C., Asangani, I.A., Ateeq, B., Chun, S.Y., Siddiqui, J., Sam, L., Anstett, M., Mehra, R., Prensner, J.R., Palanisamy, N., Ryslik, G.A., Vandin, F., Raphael, B.J., Kunju, L.P., Rhodes, D.R., Pienta, K.J., Chinnaiyan, A.M., Tomlins, S.A., 2012. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 487, 239 – 243.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
mol22014871169-sup-mmc1.pdf
Size:
5.715MB
Format:
PDF
View/Open
Name:
mol22014871169.pdf
Size:
2.921MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.